ReviewReviews in medical virology
Severe acute respiratory syndrome (SARS) coronavirus: application of monoclonal antibodies and development of an effective vaccine.
Review in Reviews in medical virology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Review
- Article
- Emergence, evolution, and vaccine production approaches of SARS-CoV-2 virus: Benefits of getting vaccinated and common questions.Saudi journal of biological sciences · 2022Review
- SARS-CoV-2 S1 is superior to the RBD as a COVID-19 subunit vaccine antigen.Journal of medical virology · 2021Article
- An overview of viruses discovered over the last decades and drug development for the current pandemic.European journal of pharmacology · 2021Review
- Coronaviruses: An Updated Overview of Their Replication and Pathogenesis.Methods in molecular biology (Clifton, N.J.) · 2020Review
- COVID-19: Coronavirus Vaccine Development Updates.Frontiers in immunology · 2020Review
- Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past.Frontiers in immunology · 2020Review
- The Hemagglutinin Stem-Binding Monoclonal Antibody VIS410 Controls Influenza Virus-Induced Acute Respiratory Distress Syndrome.Antimicrobial agents and chemotherapy · 2016Article
- Article
- Neutralizing antibody against severe acute respiratory syndrome (SARS)-coronavirus spike is highly effective for the protection of mice in the murine SARS model.Microbiology and immunology · 2009Article
- Progress towards recombinant anti-infective antibodies.Recent patents on anti-infective drug discovery · 2009Review
- A single amino acid substitution in the S1 and S2 Spike protein domains determines the neutralization escape phenotype of SARS-CoV.Microbes and infection · 2008Article
- Thiopurine analogues inhibit papain-like protease of severe acute respiratory syndrome coronavirus.Biochemical pharmacology · 2008Article
- Large-scale preparation of UV-inactivated SARS coronavirus virions for vaccine antigen.Methods in molecular biology (Clifton, N.J.) · 2008Article
- A fluorogenic peptide containing the processing site of human SARS corona virus S-protein: kinetic evaluation and NMR structure elucidation.Chembiochem : a European journal of chemical biology · 2007Article
- Synthesis and biological evaluation of nucleoside analogues having 6-chloropurine as anti-SARS-CoV agents.Bioorganic & medicinal chemistry letters · 2007Article
- Understanding the accessory viral proteins unique to the severe acute respiratory syndrome (SARS) coronavirus.Antiviral research · 2006Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SARS-CoV is a new type of human coronavirus identified as a causative agent of severe acute respiratory syndrome (SARS). On the occasion of the SARS outbreak, various monoclonal antibodies (mAbs) against SARS-CoV have been developed and applied for diagnosis, clinical management and basic research. In this review, we overview the biochemical and functional properties and applications of these SARS-CoV mAbs. We also focus on a variety of vaccines currently under development and discuss the immune response elicited by these vaccines in animal models, hopefully to better understand what we need to do next to fight against newly emerging pathogens in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.